Get the Daily Brief
Latest Biotech News
High‑res brain interfaces: minimally invasive BCI and modular cortical arrays
Two neurotechnology teams unveiled complementary platforms for high-density brain interfacing. One group reported a scalable, minimally invasive, high-resolution brain-computer interface (BCI)...
Antibody AI: adaptive diffusion design and the need for negative data
Computational antibody design advanced on two fronts: an adaptive diffusion strategy for humanizing and designing therapeutic antibodies and a separate study highlighting the essential role of...
AI accelerates protein engineering: generative models meet structure
AI-driven protein engineering shows fresh momentum with demonstrations that foundation models and sparse denoising architectures can both speed structure generation and guide functional protein...
Mass layoffs at HHS and CDC turmoil: federal public‑health workforce slashed
Two related reports documented sweeping personnel actions that disrupted federal public-health capacity. One account described overnight notices that more than 1,000 HHS and CDC staffers were...
Regeneron to seek approval after hearing‑loss gene therapy shows gains
Regeneron announced plans to seek regulatory approval after publication of New England Journal of Medicine data showing a gene therapy produced significant hearing improvement in nearly a dozen...
Sarepta moves to file first LGMD gene therapy – therapy raises missing‑gene levels
Sarepta Therapeutics said new clinical results showed its experimental gene therapy increased expression of the missing protein in an ultra‑rare form of limb‑girdle muscular dystrophy (LGMD2E) and...
Chiesi inks CRISPR deal for rare liver disease; study suggests anti‑AAV antibodies may not block therapy
Chiesi Global Rare Diseases committed up to $115 million in a collaboration with CRISPR startup Arbor Biotechnologies to develop an in vivo gene‑editing therapy for primary hyperoxaluria type 1,...
Novo exits cell therapy — BMS buys in vivo platform in $1.5B deal
Novo Nordisk disclosed it is discontinuing all cell therapy R&D, eliminating roughly 250 roles and ending programs across Parkinson’s, chronic heart failure and a Type 1 diabetes program as part...
Mass production methods and next‑gen engineering push cell therapy scalability
Two independent advances aim to address persistent manufacturing and potency bottlenecks in engineered‑cell therapeutics. A report described scalable processes for mass production of CAR‑iNK cells...
Chinese team transplants genetically modified pig liver segment into person — graft supported metabolism 38 days
Surgeons in China reported the transplant of a genetically modified pig liver segment into a patient with advanced liver tumor; the graft functioned and supported metabolic activity for 38 days...
EVG7 glycopeptide halts C. difficile while sparing beneficial gut bacteria
Researchers described EVG7, a novel glycopeptide antibiotic that prevents Clostridioides difficile recurrence while selectively sparing key commensal gut species. Preclinical data indicate the...
FDA reassigns head of orphan drug office — regulatory office leadership changed
The FDA reassigned Sandra Retzky from her role as director of the office that oversees orphan drug designations, an administration official confirmed to Endpoints News. Retzky’s reassignment...
Illumina’s genomic alliance expands — pharma partners tap 250K+ genomes for target discovery
Illumina’s Alliance for Genomic Discovery added Alnylam Pharmaceuticals and continues to attract pharma partners seeking large, phenotyped genomic datasets for drug target discovery. The AGD has...
Hoover report demands sweeping biosecurity overhaul — policy options for securing biotech
Scholars at the Hoover Institution released 'Biosecurity Really: A Strategy for Victory,' a policy report urging immediate, broad measures to secure biotechnology. Recommendations include creating...
Regeneron to seek approval: gene therapy restores hearing in children
Regeneron reported pivotal clinical data showing a gene therapy produced significant hearing improvements in nearly a dozen children with a rare genetic form of deafness, and said it will seek...
Sarepta to file for approval – gene therapy ups missing protein in LGMD 2E
Sarepta Therapeutics announced positive clinical data showing its experimental gene therapy increased expression of a missing gene in patients with an ultra-rare limb-girdle muscular dystrophy...
FDA grants accelerated OK: dordaviprone is first systemic therapy for H3(K27M) DMG
The FDA granted accelerated approval to dordaviprone for diffuse midline glioma (DMG) harboring the H3(K27M) mutation in patients aged one year and older with progressive disease after prior...
BMS pays $1.5B: Orbital buy brings in vivo CAR‑T tech
Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion in cash, adding in vivo cell-therapy technology the buyer hopes will enable CAR‑T–style reprogramming inside patients....
Novo ends cell therapy push – shutters unit, drops Type 1 programs
Novo Nordisk announced it is discontinuing its cell therapy R&D efforts as part of a company-wide reorganization under new leadership, laying off nearly all employees in the shuttered unit and...
Chinese team implants pig liver segment: graft supports patient 38 days
Surgeons in China transplanted a genetically modified pig liver segment into a patient with cancer and reported the graft supported metabolic function for 38 days before removal due to thrombotic...